期刊
INTERNAL MEDICINE
卷 41, 期 12, 页码 1118-1123出版社
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.41.1118
关键词
idiopathic pulmonary fibrosis; usual interstitial pneumonia; interstitial pneumonia associated with; systemic sclerosis; therapeutic effects; adverse effects
Objective We attempted to evaluate the feasibility (therapeutic efficacy, tolerance, and clinical courses after treatment) of pirfenidone, an anti-fibrotic drug for patients with chronic pulmonary fibroses such as idiopathic pulmonary fibrosis (IPF). Methods Open-label one-year treatment for compassionate-use. Patients or Materials: Oral pirfenidone (40 mg/ kg body weight) was administered to 8 patients with advanced IPF and 2 with interstitial pneumonia associated with diffuse systemic sclerosis. The plasma concentration of the drug was serially followed. Radiographic scores, pulmonary functions, and arterial blood oxygen pressure were compared at three time points: at one-year before treatment, at the time of entry, and at one-year after entry. Results While pirfenidone did not show a definite therapeutic effect on overall survival (2 years after entry). During one-year treatment, there was no significant deterioration in terms of chest radiographic scores and arterial oxygen pressure, and the drug was well tolerated with minimal adverse effects within the ranges observed in this study, plasma pirfenidone concentrations did not seem to relate to the appearance of adverse effects or differences in therapeutic effects. Conclusion The feasibility of Pirfenidone as a therapeutic drug was confirmed for patients with advanced pulmonary fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据